Phase Angle and Postoperative Complications in a Model of Immunonutrition in Patients with Pancreatic Cancer.
complications
immunonutrition
pancreatic cancer
phase angle
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
11 Oct 2023
11 Oct 2023
Historique:
received:
07
09
2023
revised:
08
10
2023
accepted:
09
10
2023
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
The aim of this study was to determine the influence of our own model of immunonutrition on phase angle and postoperative complications. Our goal was to establish modern prehabilitation procedures for patients operated on for pancreatic cancer. Patients with pancreatic cancer who qualified for surgical treatment were divided into two groups. Group I (20 patients; 12 with pancreatic head cancer, 8 with pancreatic tail/body cancer) was given immunonutrition (Impact Oral 3× a day, 237 mL, for 5 days before surgery, and after surgery for an average of 3.5 days). Group II (20 patients; 12 with pancreatic head cancer, 8 with pancreatic tail/body cancer) did not receive immunonutrition. Body weight, body mass index and phase angle were assessed on admission to the hospital, after preoperative immunonutrition, on the third and eighth postoperative days. C-reactive protein and Interleukin-1 α were measured on admission to the hospital, after preoperative immunonutrition, on the eighth postoperative day. Postsurgical complications were assessed via Clavien-Dindo classification. On admission to the hospital, the phase angle was 5.0° (4.70-5.85) in Group I and 5.1° (5.00-6.25) in Group II. After 5 days of using preoperative immunonutrition, it increased statistically significantly ( This study used our own model of immunonutrition in patients undergoing surgery for pancreatic cancer. The applied model of perioperative IN improved the postoperative course of patients operated on due to pancreatic cancer. Fewer complications were observed in patients in the group receiving IN. Also, the PA value increased after the 5-day preoperative IN, and the use of perioperative IN improved the PA value on the eighth postoperative day compared to the group that did not receive IN. On this day, an increase in inflammatory parameters was also observed in the group that did not receive IN. In addition, PA correlated negatively with complications. The PA can be a useful tool to assess the effectiveness of the applied IN, and thus, to predict the occurrence of postoperative complications. Therefore, there is a further need for studies on larger groups of patients.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to determine the influence of our own model of immunonutrition on phase angle and postoperative complications. Our goal was to establish modern prehabilitation procedures for patients operated on for pancreatic cancer.
METHODS
METHODS
Patients with pancreatic cancer who qualified for surgical treatment were divided into two groups. Group I (20 patients; 12 with pancreatic head cancer, 8 with pancreatic tail/body cancer) was given immunonutrition (Impact Oral 3× a day, 237 mL, for 5 days before surgery, and after surgery for an average of 3.5 days). Group II (20 patients; 12 with pancreatic head cancer, 8 with pancreatic tail/body cancer) did not receive immunonutrition. Body weight, body mass index and phase angle were assessed on admission to the hospital, after preoperative immunonutrition, on the third and eighth postoperative days. C-reactive protein and Interleukin-1 α were measured on admission to the hospital, after preoperative immunonutrition, on the eighth postoperative day. Postsurgical complications were assessed via Clavien-Dindo classification.
RESULTS
RESULTS
On admission to the hospital, the phase angle was 5.0° (4.70-5.85) in Group I and 5.1° (5.00-6.25) in Group II. After 5 days of using preoperative immunonutrition, it increased statistically significantly (
CONCLUSIONS
CONCLUSIONS
This study used our own model of immunonutrition in patients undergoing surgery for pancreatic cancer. The applied model of perioperative IN improved the postoperative course of patients operated on due to pancreatic cancer. Fewer complications were observed in patients in the group receiving IN. Also, the PA value increased after the 5-day preoperative IN, and the use of perioperative IN improved the PA value on the eighth postoperative day compared to the group that did not receive IN. On this day, an increase in inflammatory parameters was also observed in the group that did not receive IN. In addition, PA correlated negatively with complications. The PA can be a useful tool to assess the effectiveness of the applied IN, and thus, to predict the occurrence of postoperative complications. Therefore, there is a further need for studies on larger groups of patients.
Identifiants
pubmed: 37892404
pii: nu15204328
doi: 10.3390/nu15204328
pmc: PMC10609395
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical University of Bialystok
ID : SUB/1/DN/22/001/1137
Références
Pol Przegl Chir. 2020 Feb 7;92(2):8-11
pubmed: 32310821
Oncologist. 2019 May;24(5):691-701
pubmed: 30591550
Clin Nutr. 2021 Jul;40(7):4745-4761
pubmed: 34242915
Psychiatr Pol. 2017 Dec 30;51(6):1121-1131
pubmed: 29432507
Int J Surg. 2019 Jan;61:69-75
pubmed: 30540966
Pancreas. 2000 Nov;21(4):344-51
pubmed: 11075988
JPEN J Parenter Enteral Nutr. 2006 Jul-Aug;30(4):309-16
pubmed: 16804128
Int J Mol Sci. 2019 Feb 05;20(3):
pubmed: 30764482
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):207-217
pubmed: 30920778
Eur J Cancer. 2019 Feb;108:78-87
pubmed: 30654298
Nutr Cancer. 2016;68(2):225-33
pubmed: 26943500
Neoplasia. 2011 Aug;13(8):664-75
pubmed: 21847358
Int J Surg. 2016 Jul;31:93-9
pubmed: 27267949
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
World J Gastroenterol. 2021 Sep 21;27(35):5851-5889
pubmed: 34629806
Rev Endocr Metab Disord. 2023 Jun;24(3):543-562
pubmed: 36474107
BMC Cancer. 2023 Apr 17;23(1):351
pubmed: 37069556
Clin Nutr. 2020 Nov;39(11):3385-3394
pubmed: 32184025
Surgery. 2014 Jan;155(1):124-33
pubmed: 24589090
Surgery. 2010 Sep;148(3):573-81
pubmed: 20227099
Nutrition. 2020 Nov - Dec;79-80:110891
pubmed: 32731162
JPEN J Parenter Enteral Nutr. 2013 Sep;37(5 Suppl):21S-9S
pubmed: 24009246
J Am Coll Surg. 2011 Mar;212(3):385-99, 399.e1
pubmed: 21247782
Int J Environ Res Public Health. 2022 May 25;19(11):
pubmed: 35682009
J Gastrointest Surg. 2008 Jul;12(7):1193-201
pubmed: 18347879
Nutrients. 2020 Sep 12;12(9):
pubmed: 32932707
GE Port J Gastroenterol. 2020 Dec;28(1):13-25
pubmed: 33564701
Clin Nutr. 2017 Jun;36(3):623-650
pubmed: 28385477
Cancer. 2014 Jul 15;120(14):2207-14
pubmed: 24899148
J Nutr. 2016 Dec;146(12):2594S-2600S
pubmed: 27934650
J Gastrointest Oncol. 2018 Feb;9(1):17-23
pubmed: 29564167
Nutrition. 1998 Jul-Aug;14(7-8):611-7
pubmed: 9684265
Saudi J Gastroenterol. 2019 Jan-Feb;25(1):3-13
pubmed: 30588953
Clin Nutr. 2017 Feb;36(1):11-48
pubmed: 27637832
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861
pubmed: 30487695
Eur J Clin Nutr. 2018 Sep;72(9):1323-1327
pubmed: 30185857
J Electr Bioimpedance. 2021 Mar 30;12(1):1-2
pubmed: 34413916
Clin Nutr. 2021 May;40(5):2898-2913
pubmed: 33946039
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):180-189
pubmed: 34845859
World J Surg. 2014 Apr;38(4):803-12
pubmed: 24178185
Clin Nutr. 2012 Dec;31(6):817-30
pubmed: 23079762